| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615450 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 9 Pages |
Abstract
These findings suggest that discontinuation of second- or subsequent-line dasatinib after a sustained DMR of ⥠1 year is feasible, especially for patients with no history of imatinib resistance. In addition, the natural killer cell count was associated with the TFR.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Masaya Okada, Jun Imagawa, Hideo Tanaka, Hirohisa Nakamae, Masayuki Hino, Kazunori Murai, Yoji Ishida, Takashi Kumagai, Seiichi Sato, Kazuteru Ohashi, Hisashi Sakamaki, Hisashi Wakita, Nobuhiko Uoshima, Yasunori Nakagawa, Yosuke Minami,